DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,565 filers reported holding DANAHER CORPORATION in Q2 2020. The put-call ratio across all filers is 1.06 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,702,148 | +13.8% | 14,922 | +10.1% | 0.24% | +13.0% |
| Q2 2023 | $3,254,160 | -6.5% | 13,559 | -1.9% | 0.21% | -14.4% |
| Q1 2023 | $3,482,185 | +14.9% | 13,816 | +21.0% | 0.24% | +3.0% |
| Q4 2022 | $3,030,300 | +11.2% | 11,417 | +8.2% | 0.24% | +1.7% |
| Q3 2022 | $2,724,000 | +19.3% | 10,547 | +17.1% | 0.23% | +14.9% |
| Q2 2022 | $2,283,000 | +8.2% | 9,004 | +25.2% | 0.20% | +21.7% |
| Q1 2022 | $2,110,000 | -3.4% | 7,192 | +8.3% | 0.17% | -4.0% |
| Q4 2021 | $2,184,000 | +22.1% | 6,638 | +12.9% | 0.17% | +8.8% |
| Q3 2021 | $1,789,000 | +21.1% | 5,878 | +6.8% | 0.16% | +17.8% |
| Q2 2021 | $1,477,000 | +17.4% | 5,502 | -1.6% | 0.14% | +4.7% |
| Q1 2021 | $1,258,000 | +21.2% | 5,591 | +19.6% | 0.13% | +14.2% |
| Q4 2020 | $1,038,000 | +28.0% | 4,673 | +24.1% | 0.11% | +11.9% |
| Q3 2020 | $811,000 | +42.8% | 3,766 | +17.2% | 0.10% | +24.7% |
| Q2 2020 | $568,000 | +47.9% | 3,214 | +15.8% | 0.08% | +22.7% |
| Q1 2020 | $384,000 | +6.7% | 2,776 | +18.4% | 0.07% | +20.0% |
| Q4 2019 | $360,000 | +18.0% | 2,344 | +11.0% | 0.06% | +7.8% |
| Q3 2019 | $305,000 | +18.7% | 2,112 | +17.3% | 0.05% | +13.3% |
| Q2 2019 | $257,000 | +26.0% | 1,801 | +16.6% | 0.04% | +18.4% |
| Q1 2019 | $204,000 | -2.9% | 1,544 | -28.1% | 0.04% | +2.7% |
| Q1 2018 | $210,000 | -26.8% | 2,148 | -30.4% | 0.04% | -14.0% |
| Q4 2017 | $287,000 | -23.5% | 3,087 | -29.4% | 0.04% | -23.2% |
| Q3 2017 | $375,000 | -31.3% | 4,373 | -32.4% | 0.06% | -28.2% |
| Q2 2017 | $546,000 | -26.4% | 6,472 | -25.4% | 0.08% | -19.6% |
| Q1 2017 | $742,000 | -14.4% | 8,678 | -22.1% | 0.10% | -3.0% |
| Q4 2016 | $867,000 | -25.1% | 11,136 | -24.6% | 0.10% | -20.6% |
| Q3 2016 | $1,158,000 | -32.3% | 14,777 | -12.8% | 0.13% | -28.4% |
| Q2 2016 | $1,711,000 | +8.5% | 16,944 | +1.9% | 0.18% | +10.7% |
| Q1 2016 | $1,577,000 | -4.7% | 16,622 | -6.7% | 0.16% | -13.1% |
| Q4 2015 | $1,654,000 | -3.6% | 17,812 | -11.5% | 0.18% | +2.2% |
| Q3 2015 | $1,715,000 | -0.7% | 20,132 | -0.2% | 0.18% | +5.3% |
| Q2 2015 | $1,727,000 | -11.1% | 20,176 | -11.8% | 0.17% | -5.6% |
| Q1 2015 | $1,943,000 | -22.6% | 22,884 | -21.8% | 0.18% | -17.4% |
| Q4 2014 | $2,509,000 | -13.8% | 29,277 | -23.5% | 0.22% | +3.3% |
| Q3 2014 | $2,909,000 | -11.1% | 38,286 | -7.9% | 0.21% | -5.0% |
| Q2 2014 | $3,273,000 | +0.9% | 41,573 | -3.9% | 0.22% | +5.7% |
| Q1 2014 | $3,243,000 | -4.8% | 43,244 | -2.1% | 0.21% | -0.5% |
| Q4 2013 | $3,408,000 | -7.9% | 44,150 | -17.3% | 0.21% | -10.6% |
| Q3 2013 | $3,700,000 | +5.8% | 53,370 | -3.4% | 0.24% | +6.8% |
| Q2 2013 | $3,497,000 | – | 55,249 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |